Comparison · NCT01712308-8b94ded6
Treatment Monotherapy (Sotatercept) vs Treatment Combination (Ruxolitinib + Sotatercept): Anemia-response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Treatment Monotherapy (Sotatercept) vs Treatment Combination (Ruxolitinib + Sotatercept): Anemia-response. Trial comparisons, record NCT01712308-8b94ded6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01712308-8b94ded6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.296 | 0.159 | 0.485 | wilson | |
| Risk in group 2 | 0.316 | 0.154 | 0.54 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0195 | -0.283 | 0.229 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.938 | 0.389 | 2.26 | log | |
| Odds ratio, group 1 over group 2 | 0.912 | 0.256 | 3.26 | log | |
| Number needed to treat, for one fewer participant with the outcome on Treatment Monotherapy (Sotatercept) than on Treatment Combination (Ruxolitinib + Sotatercept) | 51.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Treatment Monotherapy (Sotatercept) | Patients receive sotatercept SC once every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients unable to achieve anemia-response after 8 cycles will be taken off study.~Sotatercept: Given SC | 8 | 27 | OG000 |
| Group 2 | Treatment Combination (Ruxolitinib + Sotatercept) | patients that are already on therapy with ruxolitinib (for at least for 6 months, and on stable dose for last 2 months) will continue ruxolitinib in addition to sotatercept SC once every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients unable to achieve anemia-response after 8 cycles will be taken off study.~Sotatercept: Given SC~Ruxolitinib | 6 | 19 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Anemia-response
- Description
Defined as an increase in hemoglobin level equal to or greater than 1.5 g/L without red blood cell-transfusion OR becoming red blood cell-transfusion-independent in a patient who is red blood cell-transfusion-dependent. Will be based on the intent-to-treat principle.
- Time frame
- Up to 84 days
- Population
- Of the 35 participants on the monotherapy arm, 27 were evaluable for response. Of the 21 participants on the Combination Therapy arm, 19 were evaluable for response.
Source ClinicalTrials.gov
Trial
- Title
- Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia
- NCT number
- NCT01712308
- Phases
- PHASE2
- Conditions
- Anemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis
- Interventions
- Sotatercept, Ruxolitinib
- Lead sponsor
- M.D. Anderson Cancer Center
- Results first posted
- 2023-06-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01712308?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01712308-8b94ded6